BioNTech's HIV Vaccine Study Gears Up as Patent Challenges Multiply Across Europe and Canada

BioNTech initiates phase I/II trial of mRNA HIV vaccine BNT168 while facing new patent claims from Arbutus and Sanofi; analysts upgrade stock to Hold despite revenue drop.

BioNTech is set to begin a phase I/II trial this month for BNT168, a therapeutic mRNA-based HIV vaccine that aims to achieve sustained viral suppression without antiretroviral therapy. The study, registered on July 16, 2026, will enroll 126 participants split into HIV-negative and HIV-positive cohorts. The negative group will receive three injections to test safety and immune response; the positive cohort, consisting of patients with stable viral control, will receive four injections followed by a monitored treatment pause to assess whether vaccine-induced T-cell responses can maintain viral suppression. The approach targets a functional cure for HIV, an area where mRNA technology has yet to make a clinical mark.

But the Mainz-based biotech is not just chasing a scientific first. It is also contending with a rapidly expanding patent dispute over the lipid nanoparticle (LNP) technology that underpins its mRNA platform. On July 18, Arbutus Biopharma and its partner Genevant Sciences filed three new international claims — two before the Unified Patent Court in Europe (cases PR-UPC-CFI-0002562/2026 and PR-UPC-CFI-0002566/2026, covering patents EP 4 241 767 and EP 4 495 237) and a third in Canada. The move extends a legal battle that already loomed over BioNTech and its partner Pfizer. Arbutus secured roughly $178 million from a settlement with Moderna on July 8, providing fresh funding to press its claims. It also announced plans to buy back up to $230 million of its own shares starting in the third quarter and expects a dividend from Genevant in the same period.

The patent thicket grows thicker still. On July 14, Sanofi lodged two separate infringement suits in a New Jersey district court — one against Pfizer over Comirnaty and one against Moderna over Spikevax and mNexspike. The French drugmaker leans on patents acquired through its $3.2 billion purchase of Translate Bio in 2021, asserting eight patents against Pfizer and ten against Moderna that cover mRNA purification and LNP encapsulation methods. While Sanofi is not directly suing BioNTech, the claims target the core technology used in the Pfizer-BioNTech vaccine and signal that several companies now see the LNP patent landscape as a revenue opportunity. Unlike Arbutus, Sanofi is not seeking an injunction, only "reasonable compensation" — a stance that points to a licensing demand rather than an outright block.

Analyst sentiment, meanwhile, has inched toward the cautiously optimistic side. Wall Street Zen upgraded BioNTech from "Sell" to "Hold" on July 18, while the broader consensus settled at "Moderate Buy" with an average price target of $129.12. The upgrade comes despite a 35.4% year-on-year drop in quarterly revenue, which missed expectations. Analysts pointed to the company's multi-billion-euro share buyback program as a sign of management's confidence in its pipeline beyond the COVID-19 franchise.

The stock itself has been virtually static for 30 days, closing the week at €80.20 — a rounding error on the weekly change. Shares remain roughly 24% below the 52-week high of €105.80 set in late January, and about 5.8% under the 200-day moving average of €84.90. Recovery from the March 10 low of €68.35 stands at about 17%, but the combination of clinical milestones and mounting legal exposure has investors waiting for a clearer direction. BioNTech's €16.8 billion cash pile provides ample buffer, but each new claim — whether from Arbutus, Genevant, or Sanofi — adds a layer of uncertainty to the long-term cost of doing business in mRNA therapeutics.